We hope to see you in Chicago.
ClearNote Health will be presenting new clinical data for the Avantect® Pancreatic Cancer Test at DDW 2026 — including two scientific presentations featuring validation data from our multiomics liquid biopsy platform for high-risk surveillance.
Visit us at Booth #2248 (West Hall) to speak with the team about early detection and how Avantect is changing the conversation around elevated pancreatic cancer risk.
The Avantect® Pancreatic Cancer Test is a multiomics blood-based assay integrating epigenomic 5-hydroxymethylcytosine (5hmC) patterns, genomic features from cfDNA, and glycan biomarker measurements within an optimised machine-learning algorithm — delivering a single actionable result for individuals at elevated risk.
Clinically validated in a case-control study of pancreatic cancer patients (n=259) and non-cancer subjects (n=1,186).
Designed for patients at elevated risk
Certain clinical and inherited factors are associated with significantly elevated pancreatic cancer risk. The Avantect Pancreatic Cancer Test is designed for individuals with one or more of the following:
ClearNote Health research will be presented in two sessions at DDW 2026.
Our team will be available throughout the conference for meetings and conversations.
Download the latest clinical evidence and product information for the Avantect® Pancreatic Cancer Test.
Learn how Avantect® integrates 5hmC epigenomics, genomic cfDNA features, and glycan biomarkers within a machine-learning algorithm to deliver high sensitivity and specificity for early-stage pancreatic cancer detection.
↓ Download WhitepaperA concise overview for clinicians covering risk factor criteria, clinical performance data, ordering workflow, and result interpretation to support next-step decisions in elevated-risk care.
↓ Download BrochureReferences
Visit us at Booth #2248 (West Hall). Book time with our team in advance to make the most of your conference schedule.
Schedule a MeetingImportant Information
The Avantect Pancreatic Cancer Test is an early detection test. The test does not establish a diagnosis of pancreatic cancer, and results should be considered in the context of other clinical criteria. A definitive diagnosis of cancer is rendered by clinical providers through a combined use of diagnostic testing, imaging, biopsy, and pathological findings. Not all pancreatic cancers will be detected. Some patients with pancreatic cancer may have a "Signal not detected" result. Some patients without pancreatic cancer may have a "Signal detected" result. False-negative and false-positive results are possible. A "Signal not detected" result does not guarantee that no pancreatic cancer is present. In some cases, no result is obtained. While this is very uncommon, it may be caused by shipping delays or when there is not enough cell-free DNA for the test in the patient's blood. If this happens, additional blood samples may be required to produce a patient result.
The Avantect Pancreatic Cancer Test was developed in the ClearNote Health CLIA-certified (CLIA# 05D2249973) and CAP-accredited (CAP# 9219174) laboratory and has not been cleared or approved by the US Food and Drug Administration (FDA). ClearNote Health, Inc., 10578 Science Center Drive #210, San Diego, CA 92121. Tel +1 833 258-7827.